Buerger’s disease or Thromboangiitis Obliterans (TAO) is a nonatherosclerotic segmental vascular disease which affects small and medium arteries and veins in the upper and lower extremities. Based on pathological findings, TAO can be considered as a distinct form of vasculitis that is most prevalent in young male smokers. There is no definitive cure for this disease as therapeutic modalities are limited in number and efficacy. Surgical bypass has limited utility and 24% of patients will ultimately require amputation. Recently, studies have shown that therapeutic angiogenesis and immunomodulatory approaches through the delivery of stem cells to target tissues are potential options for ischemic lesion treatment. In this review, we summarize the current knowledge of TAO treatment and provide an overview of stem cell-based treatment modalities.
CITATION STYLE
Dash, B. C., Peyvandi, H., Duan, K., Richardson, E., Ndon, S. U., Gabrick, K. S., … Hsia, H. C. (2020, November 1). Stem cell therapy for thromboangiitis obliterans (Buerger’s disease). Processes. MDPI AG. https://doi.org/10.3390/pr8111408
Mendeley helps you to discover research relevant for your work.